Taming the Medical Literature ~ For Genetic Conditions ~ Hand-Curated • Direct to You
LitAlert ~~ GeneLit.com
Similar response rates and survival with PARP inhibitors for patients with solid tumors harboring somatic versus Germline BRCA mutations: a Meta-analysis and systematic review.
Mohyuddin GR, Aziz M, Britt A, Wade L, Sun W, Baranda J, Al-Rajabi R, Saeed A, Kasi A.
BMC Cancer. 2020 Jun 3;20(1):507. doi: 10.1186/s12885-020-06948-5.
Setting a baseline: A 7-year review of referral rates and outcomes for serous ovarian cancer prior to implementation of oncologist mediated genetic testing.
Randall Armel S, Volenik A, Demsky R, Malcolmson J, Maganti M, McCuaig J.
Gynecol Oncol. 2020 Jun 3. pii: S0090-8258(20)31082-9. doi: 10.1016/j.ygyno.2020.05.014. [Epub ahead of print]
Incorporating Parp-inhibitors in Primary and Recurrent Ovarian Cancer: A Meta-analysis of 12 phase II/III randomized controlled trials.
Ruscito I, Bellati F, Ray-Coquard I, Mirza MR, du Bois A, Gasparri ML, Costanzi F, De Marco MP, Nuti M, Caserta D, Pignata S, Dorigo O, Sehouli J, Braicu EI.
Cancer Treat Rev. 2020 May 26;87:102040. doi: 10.1016/j.ctrv.2020.102040. Epub ahead of print.
The Melanoma and Breast Cancer Association: An Overview of their 'Second Primary Cancers' and the Epidemiological, Genetic and Biological correlations.
Jeyakumar A, Chua T, Lam AK, Gopalan V.
Crit Rev Oncol Hematol. 2020 May 22;152:102989. doi: 10.1016/j.critrevonc.2020.102989. Epub ahead of print.
Germline variants and phenotypic spectrum in a Canadian cohort of individuals with diffuse gastric cancer.
Aronson M, Swallow C, Govindarajan A, Semotiuk K, Cohen Z, Kaurah P, Velsher L, Ambus I, Buckley K, Forster-Gibson C, Meschino WS, Blumenthal A, Kim RH, Brar S.
Curr Oncol. 2020 Apr;27(2):e182-e190. doi: 10.3747/co.27.5663. Epub 2020 May 1.